Latest Indian Price Caps Face Early Industry Dissent
This article was originally published in Scrip
The Indian regulator's latest move capping prices of over 100 formulations appears to be facing some dissent with industry moving a review application over what it claims are certain untenable requirements especially for drugs already being sold below the ceiling price.
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.